---
title: "Gan & Lee Pharmaceuticals Registers Diabetes Treatment Drug"
date: "2025-02-11 11:09:18"
summary: "Gan &amp; Lee Pharmaceuticals  obtained drug registration from China's drug administrator for empagliflozin tablets. The drug is an SGLT-2 inhibitor for diabetes treatment, according to a Tuesday filing with the Shanghai bourse. Shares of the pharmaceutical company were down 2% in recent trade."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Gan & Lee Pharmaceuticals obtained drug registration from China's drug administrator for empagliflozin tablets.

The drug is an SGLT-2 inhibitor for diabetes treatment, according to a Tuesday filing with the Shanghai bourse.

Shares of the pharmaceutical company were down 2% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465973:0/)
